本课题拟检测乳腺癌患者肿瘤组织HSP70-HER蛋白表达，首先用我们建立的方法分析乳腺癌HSP70-HER表达谱并对其免疫原活性进行研究，探讨通过人工干预HSP70-HER蛋白消除肿瘤患者免疫耐受，增强HSP70-HER蛋白诱导自体特异性CD8+NKT细胞抗肿瘤活性的方法。①自乳腺癌组织中分离纯化HSP70-HER蛋白复合物，对人乳腺癌HSP70-HER谱进行分类。②对比每类自体HSP70-HER特异性CD8+NKT细胞抗肿瘤活性，结合各组HSP70-HER蛋白复合物包含的抗原成分，探讨出现差异的原因。③通过加入重组人蛋白抗原进行人工干预增强HSP70-HER特异性CD8+NKT细胞抗肿瘤活性。本研究通过分析乳腺癌患者HSP70-HER谱，探讨诱导高效肿瘤特异性自体CD8+NKT细胞新方法，目的是消除乳腺癌患者的免疫耐受，提高乳腺癌免疫治疗效果，为乳腺癌患者个体化免疫治疗提供新的思路。

This study detects the HSP70-HER expression in tumor tissue of breast cancer patients. First,using the method established by our group, we analyze the HSP70-HER list of breast cancer and invest its immunocompetence. Second, using artificial intervention of HSP70-HER complexes, investigate the method of eliminating immune tolerance and enhancing the antineoplastic activity of HSP70-HER specific CD8+NKT cells. ① Purify the HSP70-HER complexes from breast tumor tissues, and classify the them according to the HSP70-HER list. ② Research the antigenic components of the HSP70-HER complexes. Contrast the anti-tumor activities of every kind of HSP70-HER specific CD8+NKT cells and discover the reason of the difference among them. ③ Artificial intervention the immune complexes by addition recombinant proteantigen to enhancing the anti-tumor activities of HSP70-HER specific CD8+NKT cells. By analyzing the HSP70-HER list of breast caner, this study researchs the improved method for inducing autologous tumor-specific CD8+NKT cells. The purpose is eliminates immune tolerance and boosts the immunotherapy efficacy of breast cancer. This research will provide a new approch for individuated immunotherapy for breast cancer.